timothy sykes logo

Stock News

Clear Street Boosts Annexon with Buy Rating Tied to Promising Study Results

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Updated 12/20/2025, 11:13 am ET 12/20/2025, 11:13 am ET | 5 min 5 min read
Clear Street Boosts Annexon with Buy Rating Tied to Promising Study Results Thumbnail

Annexon Inc. stocks have been trading up by 8.86 percent after unveiling hopeful drug trial outcomes.

Healthcare industry expert:

Analyst sentiment – positive

Annexon (ANNX) is currently positioned precariously in the healthcare industry, particularly given its negative pretax profit margin of -34447.1% and concerning profitability metrics. With a negative operating cash flow of -$52,304,000 and a significantly impaired balance sheet reflecting a return on equity of -61.98%, the company denotes substantial ongoing losses. Despite holding an enterprise value of $209,420,000 and a relatively low total debt-to-equity ratio of 0.17, Annexon is grappling with operational inefficiencies as evidenced by a substantial free cash flow deficit of -$52,352,000 alongside a stark negative EBIT of -$54,922,000 indicating operational challenges primarily driven by high R&D expenditures aimed at future growth.

In technical terms, Annexon exhibits recent volatile price behavior. Over the short term, there’s discernible upward pressure especially seen in the upward gap on December 19, where the price spiked to a high of $5.2471, closing at this level. The series of movements suggest a nascent bullish trend supplemented by favorable insider transactions. Notably, the statically low volume trading range preceding the recent price surge could suggest accumulation by strategic investors, offering a tactical entry point. Current price support is identified around $4.80, with resistance anticipated at $5.25, which, if breached, signifies potential upward momentum. Short-term traders could enter long positions near support, targeting the defined resistance with stop-losses strategically placed slightly below $4.70.

Annexon’s near-term outlook is bolstered by strategic insider purchases by director Muneer A Satter, reflecting robust internal confidence. These purchases have sparked an 8.6% surge in stock value, indirectly strengthening its market positioning despite recent losses. The initiation of coverage by Clear Street with a ‘Buy’ rating and a $17 price target, underscores optimism around the promising Phase 2 study results for vonaprument. Comparatively, within the healthcare sector and Biotechnology & Life Sciences benchmarks, ANNX’s aggressive research intensifies its growth potential, albeit bearing higher risk. Support levels near $4.80 and market agreement on positive catalysts provide a cautiously optimistic narrative for its stock, suggesting a conducive environment for longer-term investments.

Candlestick Chart

Weekly Update Dec 15 – Dec 19, 2025: On Saturday, December 20, 2025 Annexon Inc. stock [NASDAQ: ANNX] is trending up by 8.86%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Annexon’s financial metrics reflect a turbulent journey marked by considerable efforts in leveraging strategic assets. With a notable close at $5.2471 on December 19, 2025, the stock displayed resilient tendencies following previous fluctuations. Tactical insider activities and market responses catalyzed this stabilization, despite the complex backdrop of financial statements showing significant losses. The company registered a total debt-to-equity ratio at 0.17, reaffirming its ability to manage existing liabilities effectively with accessible resources.

More Breaking News

The current ratio stands impressively at 4.4, suggesting a robust capacity for fulfilling short-term obligations, notwithstanding the daunting net income figure of -$54.92M. This paints an image of a firm persistently engaging in operational improvements amidst substantial expenses. Importantly, these initiatives are backed by key metrics like high enterprise value pegged at approximately $209M, despite the negative pressure from negative cash flows and earnings per share (EPS).

Conclusion

In summary, Annexon’s strategic narrative is being shaped through both clinical advancements and substantive insider engagements that bolster market sentiments. As millionaire penny stock trader and teacher Tim Sykes says, “Preparation plus patience leads to big profits.” The convergence of these factors, coupled with promising Price-to-Tangible-Book ratios and the noteworthy response from influential stakeholders, sets a considerable stage for future growth endeavors. Market observers are likely to monitor closely the unfolding impacts of these developments and how they thread into broader financial strategies that Annexon advances into the new year. This strategic patience is pivotal for traders who are keenly observing Annexon’s unfolding story and aligning their moves accordingly.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”